CoChat

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

Open access
Kumar, Shaji K., Lacy, Martha Q., Hayman, Suzanne R., Stewart, Keith, Buadi, Francis K., Allred, Jacob, Laumann, Kristina, Greipp, Philip R., Lust, John A., Gertz, Morie A., Zeldenrust, Steven R., Bergsagel, P. Leif, Reeder, Craig B., Witzig, Thomas E., Fonseca, Rafael, Russell, Stephen J., Mikhael, Joseph R., Dingli, David, Rajkumar, S. Vincent, Dispenzieri, Angela · 2011 · American Journal of Hematology
Cited by 61

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The combination of lenalidomide and low‐dose dexamethasone is an effective treatment for multiple myeloma (MM). Addition of alkylating agents to lenalidomide or thalidomide results in increased response rates and deeper responses. We designed this trial to study the combination of cyclophosphamide, lenalidomide, and dexamethasone (CRd) as initial therapy for MM. Fifty‐three patients with previously untreated symptomatic MM was enrolled. Patients received 4‐week treatment cycles consisting of lenalidomide (25 mg daily for 3 weeks), dexamethasone (40 mg weekly), and cyclophosphamide (300 mg/m 2 weekly for 3 weeks). A partial response or better was seen in 85% of patients including 47% with a very good partial response or better. The toxicities were manageable with over 80% of planned doses delivered; six patients went off study for toxicity. The median progression free survival (PFS) for the entire group was 28 months (95% CI: 22.7–32.6) and the overall survival (OS) at 2 years was 87% (95% CI: 78–96). Importantly, 14 patients with high‐risk MM had similar PFS and OS as the standard‐risk patients (n = 39). CRd is an effective and well‐tolerated regimen for upfront therapy of MM with high response rates and excellent 2‐year OS, and is suitable for long‐term therapy. Am. J. Hematol. 2011. © 2011 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.22053

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 61

Metadata

Authors
Kumar, S. K., Lacy, M. Q., Hayman, S. R., Stewart, K., Buadi, F. K., Allred, J., Laumann, K., Greipp, P. R., Lust, J. A., Gertz, M. A., Zeldenrust, S. R., Bergsagel, P. L., Reeder, C. B., Witzig, T. E., Fonseca, R., Russell, S. J., Mikhael, J. R., Dingli, D., Rajkumar, S. V., & Dispenzieri, A.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2011-05-31
Volume
86
Issue
8
Pages
640-645
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W2056586434
Cited by
61
References
9
FWCI
5.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. https://app.cochat.ai/papers/10.1002/ajh.22053
The paper
Kumar, S. K., Lacy, M. Q., Hayman, S. R., Stewart, K., Buadi, F. K., Allred, J., Laumann, K., Greipp, P. R., Lust, J. A., Gertz, M. A., Zeldenrust, S. R., Bergsagel, P. L., Reeder, C. B., Witzig, T. E., Fonseca, R., Russell, S. J., Mikhael, J. R., Dingli, D., Rajkumar, S. V., & Dispenzieri, A. (2011). Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology. https://doi.org/10.1002/ajh.22053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.